4/A: Citius Oncology CFO Granted 825,000 Restricted Stock Units

Citius Oncology's Chief Financial Officer, Jaime Bartushak, was granted 825,000 restricted stock units vesting in 2028.

Summary

• Jaime Bartushak, Chief Financial Officer of Citius Oncology, Inc. (CTOR), was granted 825,000 shares of common stock in the form of restricted stock units.
• The grant date for these restricted stock units is September 19, 2025.
• The shares will vest in full on the third anniversary of the grant date, which is September 19, 2028.
• Vesting is contingent upon Ms. Bartushak's continuous service to Citius Oncology, Inc. or a related entity.
• The transaction price for these units was $0.
• Following this transaction, Ms. Bartushak beneficially owns 825,000 shares.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a key executive is generally a positive sign, indicating alignment of interests and a retention strategy. The future vesting date means no immediate impact, but it signals confidence in long-term value creation.

Positives

• The grant of 825,000 restricted stock units to the CFO aligns management's interests with long-term shareholder value.
• The vesting schedule, requiring continuous service until September 19, 2028, promotes executive retention.

Negatives

• No immediate cash value is realized by the CFO, as the units are restricted and vest in the future.
• The value of the grant is dependent on the future stock performance of Citius Oncology, Inc.

Risks

• The value of the restricted stock units is subject to the future performance of Citius Oncology, Inc.'s common stock.
• Vesting is contingent on continuous service, meaning the CFO could forfeit the units if employment ceases before the vesting date.

Future Outlook

The grant of restricted stock units with a three-year vesting period indicates a long-term commitment to the company's future performance and executive retention strategy.

Industry Context

Equity grants, particularly restricted stock units with performance or time-based vesting, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, aiming to align executive incentives with long-term company growth and shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) is a common practice in the biotech industry for executive compensation, similar to companies like Moderna or BioNTech, which frequently use equity to incentivize leadership.
• A three-year cliff vesting schedule, as seen here, is a typical retention mechanism, comparable to vesting schedules observed at early-stage growth companies in the pharmaceutical sector.
• The $0 price for the acquisition of RSUs is standard for grants, reflecting compensation rather than a direct purchase.

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of CFO's interests with long-term stock performance.
• Employees: May signal stability in executive leadership and a commitment to long-term growth.

Next Steps

• The restricted stock units will vest in full on September 19, 2028, subject to continuous service.

Key Dates

Recommendation

This filing reports a routine executive equity grant, which is a standard compensation practice designed to align management incentives with long-term shareholder value. While positive for executive retention and alignment, it does not present new information that would fundamentally alter the investment thesis or warrant a change in current position. Investors should continue to monitor the company's operational and financial performance.

Keywords

Citius Oncology, CTOR, Restricted Stock Units, RSU, Executive Compensation, Insider Ownership, Form 4, Jaime Bartushak, CFO, Equity Grant, Vesting